Navigation Links
Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
Date:4/21/2008

Reagent-Free Preparative Transfection Eliminates the Need to Engineer Stable Cell Lines and Enables the use of Primary Cells for Cell Based Assays and Screening

GAITHERSBURG, Md., April 21 /PRNewswire-USNewswire/ -- MaxCyte announces today the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology. This system enables rapid and efficient transfection of any kind of cell or cell line with any molecule (plasmids, proteins, protein complexes, drugs, mRNA, siRNA), at scales ranging from micro-liters to liter volumes.

MaxCyte's ITF Inline Transfection System enables transient transfection of cell lines as well as primary cells, and is now available for drug discovery and screening applications. The sterile, closed system provides unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods.

Many cell based assays and research projects are based on recombinant cell lines. Optimizing such cell lines so they express a desired set of properties and are compatible with a particular screening platform takes considerable time and expense. Because of its ease and speed, transient transfection is increasingly used to replace cloning and recombinant work in a wide range of applications (e.g. ion channel based drug or GPCR screening). The cost-effective MaxCyte ITF Inline Transfection system replaces current preparative transfection technologies which depend on expensive and complicated virus constructs, lipid based transfection agents, or small scale electroporation devices.

The high efficiency and viability of cells processed by the MaxCyte ITF Inline Transfection System make it possible to focus on biologically relevant cell lines, and even primary cells. Inline transfection is also fully scalable. It can be used to transfect 10^5 - 10^7 cells in seconds and up to 10^10 cells in less than 30 minutes. Viability is routinely greater than 90%, with more than 90% cell loading and transfection efficiency for many cell lines. Protocols are available for a wide range of cell lines and primary cells.

About MaxCyte

The MaxCyte transfection platform was first designed, developed, and commercialized for cell-based therapies and is currently used in human therapeutic applications. This technology is now available for research purposes under a limited label license.

The Company's proprietary, non-viral, ex vivo cell loading technology provides safety, scalability and reproducibility fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered progenitor cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine with more than 16 commercial and academic partners currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com/cell-based-screening.shtml


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
2. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
3. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
4. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
5. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
6. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
7. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
11. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 2017   PDI , a leader in infection ... an educational session focused on the role of chlorhexidine ... at the 2017 Annual Scientific Meeting of the Association ... at the Phoenix Convention Center ... 16-19, will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/1/2017)... Sept. 1, 2017 Michael Penna , ... , highlights opportunities for growth in his response to ... Marlin Equity is seeking a buyer for eMDs. Penna,s ... 22-year-old healthcare solutions Value Added Reseller and national leader ... "As the healthcare market continues to ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, ... the creation of published author, Colleen Crispi, has owned four beauty salons and written ... involved in real estate and cooking. , “The doctor’s office was only three ...
(Date:9/19/2017)... ... 2017 , ... Only a few physicians were selected to receive the prestigious ... Clevens, MD, FACS . The founder and medical director of Clevens Face and ... at Yale, Harvard and the University of Michigan. He has served patients throughout Central ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill gaps, provide essential insights, ... enhanced service delivery and operations by leveraging PAPA Healthcare’s post-acute productivity and analytics ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor ... USAID’s Innovation to Action Award. , The Innovation to Action Award, a ...
(Date:9/19/2017)... ... 19, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... national Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted ...
Breaking Medicine News(10 mins):